24-24 April 2023
Qmed+
REGISTER NOW
keyboard_arrow_left See all news

Recent News

27 Sep, 2022 /
Nordson Medical
Nordson MEDICAL Opens Tecate Mexico Medical Device Manufacturing Facility
Nordson MEDICAL announces the official opening of its Tecate, Mexico, Medical Device Man...
14 Sep, 2022 /
Qosina
Qosina Expands Class VI Tubing Portfolio for Single-Use Medical Device and Bioprocess Applications
Qosina expands its Class VI tubing portfolio with several new brands
26 Aug, 2022 /
Smalley
Smalley Wins GM Supplier Quality Excellence Award for 10th Consecutive Year
Smalley receives the General Motors Supplier Quality Excellence Award for the 10th conse...
26 Jul, 2022 /
Qosina
Qosina Adds the AseptiQuik STC Series to Its Line of Steam-Thru Connectors
Qosina introduces the AseptiQuik® STC connectors to its line of Steam-Thru® connectors
08 Jul, 2022 /
Smalley
Smalley Europe Celebrates 20 Years of Local Service
Smalley celebrates 20 years in the European market
Evonik
/ 24 Feb, 2022
keyboard_arrow_left See all news

Evonik achieves major biotech breakthrough with a new animal-free and fermentation-based collagen platform

“This is arguably our biggest innovation breakthrough in recent years: a fermentation-based collagen platform that can effectively substitute the use of animal-derived collagen in pharmaceutical, medical, and cell culture markets.” said Dr. Thomas Riermeier, SVP and General Manager for the Health Care business line of Evonik. “We look forward to working with customers to develop the next-generation collagen products with an improved safety profile.”

Evonik's proprietary collagen platform features a triple helix structure and other biological properties that mimic many of the attributes of natural collagen so it can reliably interact with cells and tissues and be readily absorbed or remodelled by the body.
Animal-sourced collagen, currently the main source of collagen for use in life sciences, can be associated with batch-to-batch variability, potential transmission of diseases or pathogens, adverse immunogenic or allergic reactions, and non-sustainable sourcing methods. Evonik’s collagen is produced under controlled conditions via a fermentation-based process. In addition to being sustainable and suitable for vegan use, this process delivers an ultra-high level of purity that is easily reproducible at any commercial scale.

Evonik will utilize its established fermentation process technologies and global manufacturing network to commercialize the collagen platform for worldwide use. The Company's application, formulation and manufacturing competencies will also be used to help customers develop and commercialize their own biofabricated products.

The new collagen platform will also support Evonik's Tissue Engineering Project House, which was launched in Singapore in 2018 by the Company's strategic innovation unit Creavis, to develop advanced biomaterial solutions in regenerative medicine.
Processing. Please wait.
Loading...